Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharma AidsDHA:PHARMAID -2.55%73 Interest Coverage is 44.93 as of Mar. 2026, which is 28% below its 10-year median of 62.52. GuruFocus rates DHA:PHARMAID with a GF Score™ of 73/100 and a GF Value™ of BDT758.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 466 Medical Devices & Instruments companies, Pharma Aids ranks better than 65.02% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Pharma Aids's
Operating Income
for the
three
months ended in Mar. 2026 was BDT26.2 Mil. Pharma Aids's Interest Expense for the
three
months ended in Mar. 2026 was BDT-0.6 Mil.
Pharma Aids's interest coverage for the quarter that ended in Mar. 2026 was 44.93.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Pharma Aids's Interest Coverage or its related term are showing as below:
DHA:PHARMAID'
s Interest Coverage Range Over the Past 10 Years
Min: 16.87 Med: 62.52 Max: 326.92
Current: 41.89
DHA:PHARMAID's Interest Coverage is ranked better than 65.02% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 16.08
vs DHA:PHARMAID: 41.89
Pharma Aids (DHA:PHARMAID) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Pharma Aids Interest Coverage Related Terms
Pharma Aids Interest Coverage Historical Data
* Premium members only.
The historical data trend for Pharma Aids's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
DHA:PHARMAID vs ISRG, BDX, MDLN: Interest Coverage Comparison
For the Medical Instruments & Supplies subindustry, Pharma Aids's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Aids Interest Coverage vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pharma Aids's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Pharma Aids's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Aids (DHA:PHARMAID) has a Interest Coverage of 44.93 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharma Aids and its competitors. This is 28% below median its historical median of 62.52. Over the past decade, Pharma Aids' Interest Coverage has ranged from 16.87 to 326.92. According to the industry distribution chart, Pharma Aids ranks #163 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 35%.
Is Pharma Aids' Interest Coverage too high?
Pharma Aids' current Interest Coverage of 44.93 is 28% below median its 10-year median of 62.52. Over the past 10 years, this metric has ranged from a low of 16.87 to a high of 326.92. The Medical Devices & Instruments industry median Interest Coverage is 16.08. Pharma Aids' value of 44.93 is 179.4% above this industry median. Based on the distribution chart, Pharma Aids ranks #163 out of 466 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Pharma Aids has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Aids' Interest Coverage compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Pharma Aids ranks #163 out of 466 companies for Interest Coverage. This puts Pharma Aids in the upper half of its industry. The industry median Interest Coverage is 16.08. Pharma Aids' value of 44.93 is 179.4% above this benchmark. Historically, Pharma Aids' own Interest Coverage has ranged from 16.87 to 326.92 over the past decade. While the company's 10-year median is 62.52 vs. the industry median of 16.08, Pharma Aids has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Medical Devices & Instruments company?
The median Interest Coverage among Medical Devices & Instruments companies is 16.08, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Aids's current Interest Coverage of 44.93 is 179.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Pharma Aids and its competitors. For the Medical Devices & Instruments industry, the median Interest Coverage is 16.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Aids's current Interest Coverage is 44.93, which is 28% below median its own 10-year median of 62.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Aids stock overvalued right now?
Based on GuruFocus' analysis, Pharma Aids (DHA:PHARMAID) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT758.56, compared to a current price of BDT644.70 — trading 15% below its estimated fair value. The current Interest Coverage is 44.93, which is 28% below median its 10-year median of 62.52 and 179.4% above the Medical Devices & Instruments industry median of 16.08. Pharma Aids' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Pharma Aids (DHA:PHARMAID), the current Interest Coverage is 44.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Aids (DHA:PHARMAID) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Aids stock appears to be undervalued.
The current stock price of BDT644.70 is trading 15% below its estimated GF Value™ of BDT758.56.
GuruFocus considers Pharma Aids to be Modestly Undervalued.
Key valuation signals for DHA:PHARMAID:
Interest Coverage: 44.93 (28% below median its 10-year median of 62.52)
GF Value™: BDT758.56 vs. price of BDT644.70 (15% below fair value)
Industry Position: 179.4% above the Medical Devices & Instruments median (#163 of 466)
No single metric tells the full story. See the DHA:PHARMAID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Aids Ltd is a Bangladesh-based company engaged in the manufacturing of neutral glass ampoules, USP Type-I. Ampoules are used by pharmaceutical companies for filling liquid injections. The company produces different sizes of ampoules from 1ml to 25ml, in Clear and Amber color, and in Amber color, and of both Open Mouth (Form B and C) and Close Mouth (Form D, Din and Marzocchi type).
73GF Score
Get the complete analysis for DHA:PHARMAID
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:PHARMAID has been successfully added to your 
